GlassScriptPhysician profile
Lyn Nhoung
NPI 1689949729
$8,905.26
in general payments reported to CMS, 2019-2025
35 companies · $2,115 in 2025
The $2,115 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $260 · 2022: $1,474 · 2023: $2,377 · 2024: $2,678 · 2025: $2,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,135 · Education: $36.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,134.66 |
| Education | $36.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,918.79 | 2021-2025 | |
| Janssen Biotech, INC. | $868.25 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $787.03 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $620.96 | 2021-2025 | |
| Pfizer INC. | $614.87 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $486.33 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Lilly USA, LLC | $455.42 | 2024-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $442.20 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Celgene Corporation | $360.41 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $321.90 | 2022-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $299.09 | 2024-2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $272.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $203.47 | 2022-2023 | Rebyota |
| Alnylam Pharmaceuticals INC. | $170.44 | 2023-2025 | Givlaari |
| Phathom Pharmaceuticals, INC. | $154.70 | 2023-2025 | Voquezna |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $142.56 | 2023-2024 | Hadlima, Renflexis |
| Genzyme Corporation | $104.21 | 2022-2025 | |
| Redhill Biopharma INC. | $77.83 | 2022-2024 | Talicia |
| Regeneron Healthcare Solutions, INC. | $74.60 | 2023-2024 | Dupixent |
| Daiichi Sankyo INC. | $72.03 | 2022-2025 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.40 | 2023-2024 | Cyltezo |
| Evoke Pharma, INC. | $51.33 | 2024 | |
| Celltrion USA INC. | $49.93 | 2023-2025 | Yuflyma, Vegzelma |
| Mylan Institutional INC. | $42.78 | 2023 | Hulio |
| Qol Medical, LLC | $42.20 | 2024 | Sucraid |
| Braintree Laboratories, INC. | $28.83 | 2021-2024 | Suflave |
| Fresenius Kabi USA, LLC | $28.02 | 2023 | Idacio |
| Aimmune Therapeutics, INC. | $24.76 | 2025 | Zenpep |
| Phadia US INC. | $22.60 | 2023 | Immunocap |
| Merck Sharp & Dohme LLC | $21.92 | 2021 | |
| Exact Sciences Corporation | $17.15 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $15.84 | 2022 | |
| Dynavax Technologies Corporation | $15.70 | 2021 | |
| Intra-Sana Laboratories | $13.50 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Digestive Care, INC. | $13.22 | 2023 | Pertzye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyn Nhoung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.